Regeneron Pharmaceuticals Inc. (REGN) News
Filter REGN News Items
REGN News Results
|Loading, please wait...|
REGN News Highlights
- REGN's 30 day story count now stands at 22.
- Over the past 22 days, the trend for REGN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- CTMX, AVDL and PD are the most mentioned tickers in articles about REGN.
Latest REGN News From Around the Web
Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.
Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold US$7.0m worth of stock suggesting impending weakness.
In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company...
Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.
Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.
Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or "P/E") ratio of...
CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.
Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 28% CAGR over the last three years
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN).